[go: up one dir, main page]

BR0317132A - Métodos de diagnóstico e tratamento de doença pulmonar intersticial - Google Patents

Métodos de diagnóstico e tratamento de doença pulmonar intersticial

Info

Publication number
BR0317132A
BR0317132A BR0317132-9A BR0317132A BR0317132A BR 0317132 A BR0317132 A BR 0317132A BR 0317132 A BR0317132 A BR 0317132A BR 0317132 A BR0317132 A BR 0317132A
Authority
BR
Brazil
Prior art keywords
present
treatment
protein
methods
gene
Prior art date
Application number
BR0317132-9A
Other languages
English (en)
Inventor
Jeffrey A Whitsett
Stephen A Glasser
Original Assignee
Chidren S Hospital Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chidren S Hospital Medical Ct filed Critical Chidren S Hospital Medical Ct
Publication of BR0317132A publication Critical patent/BR0317132A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS DE DIAGNóSTICO E TRATAMENTO DE DOENçA PULMONAR INTERSTICIAL". A presente invenção refere-se um método de tratamento de doença pulmonar em um indivíduo compreendendo a administração, a um indivíduo que precisa de tal tratamento, de uma quantidade terapeuticamente eficaz de uma formulação compreendendo um produto terapêutico de SP-C. De preferência, o produto terapêutico de SP-C é um agente selecionado do grupo consistindo em uma proteína SP-C isolada, uma molécula de ácido nucléico isolada que codifica uma proteína SP-C, um anticorpo receptor de SP-C específico que estimula a atividade do receptor ou uma composição farmaceuticamente aceitável dos mesmos. A presente invenção também proporciona métodos de produção de um camundongo com uma ruptura alvejada em um gene da proteína C tensoativa (SP-C). a presente invenção também proporciona um camundongo transgênico produzido através de uma ruptura alvejada em um gene da proteína C tensoativa (SP-C). A presente invenção ainda proporciona uma célula ou linhagem de célula de um camundongo transgênico produzida através de ruptura em um gene da proteína C tensoativa (SP-C).
BR0317132-9A 2002-12-09 2003-12-09 Métodos de diagnóstico e tratamento de doença pulmonar intersticial BR0317132A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43194902P 2002-12-09 2002-12-09
PCT/US2003/038915 WO2004056310A2 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease

Publications (1)

Publication Number Publication Date
BR0317132A true BR0317132A (pt) 2005-10-25

Family

ID=32681947

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317132-9A BR0317132A (pt) 2002-12-09 2003-12-09 Métodos de diagnóstico e tratamento de doença pulmonar intersticial

Country Status (7)

Country Link
EP (1) EP1589980A4 (pt)
JP (1) JP2006519588A (pt)
CN (1) CN100401896C (pt)
AU (1) AU2003302740A1 (pt)
BR (1) BR0317132A (pt)
CA (1) CA2507613A1 (pt)
WO (1) WO2004056310A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
EP2391379B1 (en) * 2009-01-30 2017-08-02 Alphabeta AB Compound and method for treatment of alzheimer's disease
US8785391B2 (en) 2010-06-24 2014-07-22 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
JP6227523B2 (ja) 2011-04-05 2017-11-08 アルファベータ・エービーＡｌｐｈａＢｅｔａ ＡＢ 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット
US20170296595A1 (en) * 2014-09-18 2017-10-19 North Carolina State University Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
CN111972354B (zh) * 2019-05-24 2021-11-30 凯斯艾生物科技（苏州）有限公司 一种具有自身免疫特征的间质性肺炎模型的构建方法
CN111296364B (zh) * 2019-10-27 2022-06-24 上海莱士血液制品股份有限公司 一种基因改造的小鼠动物模型基因改造方法及其应用
EP3811777B1 (en) 2019-10-27 2024-07-31 Shanghai RAAS Blood Products Co., Ltd. Genetically modified non-human animals humanised for protein c
US20230135877A1 (en) * 2020-04-08 2023-05-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN115772539B (zh) * 2022-11-17 2024-06-21 南京医科大学 一种具有ⅰ型气管发育不全表型的双侧肺脏缺失小鼠模型及其构建方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0164235B1 (ko) * 1993-01-13 1999-01-15 도바 다다스 신규한 세포 표층 단백질
US6020307A (en) * 1997-04-25 2000-02-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
EP1189625A1 (en) * 1999-06-11 2002-03-27 Byk Gulden Lomberg Chemische Fabrik GmbH Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)

Also Published As

Publication number Publication date
WO2004056310A2 (en) 2004-07-08
CA2507613A1 (en) 2004-07-08
JP2006519588A (ja) 2006-08-31
WO2004056310A3 (en) 2005-09-01
AU2003302740A1 (en) 2004-07-14
CN100401896C (zh) 2008-07-16
EP1589980A2 (en) 2005-11-02
CN1731932A (zh) 2006-02-08
EP1589980A4 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
Kanaan et al. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain
Salkowski et al. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling.
CN109803977A (zh) 核酸产品及其施用方法
TW200819140A (en) High frequency application of botulinum toxin therapy
CN106924216A (zh) 纳米颗粒组合物、其制剂和它们的用途
JPH05502443A (ja) 幹細胞の成長阻害法
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
JP2003505343A (ja) ボツリヌス神経毒を含む治療薬
US9834764B2 (en) Compositions and methods of using chondroitinase ABCI mutants
CN109464393A (zh) 纳米颗粒组合物
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
JP2014503587A (ja) 界面活性剤組成物
MX2014004792A (es) Metodo de tratamiento o reduccion de efp.
CN110381976A (zh) 包括肽wkdeagkplvk的组合物
BR0317132A (pt) Métodos de diagnóstico e tratamento de doença pulmonar intersticial
US20190381140A1 (en) Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
US20210162029A1 (en) Compositions and methods for treatment or prevention of skin diseases and disorders with lekti
JP2020532316A (ja) 局所用組成物及び使用
JP2022510377A (ja) 状態の処置のための組成物
JP5208135B2 (ja) 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物
MXPA04003773A (es) Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.
CN117157049A (zh) Atp合酶抑制剂-化妆品和治疗用途
CA2342770A1 (en) Ly6h gene
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
Ma et al. Successful application of a galanin-coated scaffold for periodontal regeneration

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired